Equity Field Notes from temporal sources

[DanWebzster]

ALIM is a slow growth, unprofitable company with one good product.

markets opthalmic drug delivery device for Diabetic Macular Edema (DME)

continues to conduct post-approval studies to scientifically support marketing efforts.

Installations last a minimum of 3 years. Company may not be significantly profitable until they reach the point when their market includes new installations + re-installations.

ALIM's partner in the EU will submit data to expand the device into the Uveitis indication. They will submit this data in Q3/2018 and approval could come in H-1/2019.

Q1/2018 report showed their operational losses declining and $23.8mn
in cash. Re-installation in the European market should begin in 2019.

It would be a nice opportunity to see this stock experience tax loss selling in 2018